Navigation Links
Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
Date:10/27/2009

TARRYTOWN, N.Y., Oct. 27 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 18th Annual Credit Suisse Healthcare Conference on Wednesday, November 11, 2009. The presentation is scheduled for 1:30 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page under the Presentations heading. An archived version of the presentation will be available after the live webcast through December 13, 2009. Additional information about Regeneron and recent news releases are available on the Regeneron web site.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders.

    Contacts Information:

    Peter Dworkin                             Laura Lindsay
    Investor Relations                        Media Relations
    914.345.7640                              914.345.7800
    peter.dworkin@regeneron.com               laura.lindsay@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Inverness Medical Innovations Announces Third Quarter 2009 Results
5. Logical Therapeutics Announces Positive Results of LT-NS001 vs. Naproxen Clinical Study
6. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
7. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
8. Genomma Lab Internacional Announces Third Quarter 2009 Results
9. ATS Medical Announces Third Quarter 2009 Earnings Release Date and Conference Call
10. Trubion Announces Upcoming Presentation at 8th Annual BIO Investor Forum
11. Sequenom Announces Paul Maier to Become Interim Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... 2017 Research and Markets has announced ... 2014-2025" report to their offering. ... The global digestive enzyme ... 2025. Growing consumer awareness regarding the severity of digestive disorders ... stimulate industry growth over the forecast period. The increasing incidence ...
(Date:2/28/2017)... , Feb 28, 2017 ... Research and Markets has ... report to their offering. The global orthobiologics ... The orthobiologics market is predominantly driven by the ... innovations in biomaterials, used in the production of orthobiologics are presumed ...
(Date:2/27/2017)... Health, Inc. (NYSE: HYH ) today reported fourth ... and related key planning assumptions. Executive Summary 2016 ... increase compared to the prior year. Net ... to net income of $15 million in the fourth quarter ... compared to adjusted net income of $27 million in the ...
Breaking Medicine Technology:
(Date:2/28/2017)... ... February 28, 2017 , ... Las Vegas Skin and Cancer Clinic (LVSCC) ... Friday, March 10, 2017, 4-7 pm PST. For more than six decades, LVSCC has ... the South Rancho neighborhood, has been renovated to provide medical and cosmetic dermatological products ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... healthcare automation intelligence company based in New York. , “Ensuring an intuitive, user-friendly ... workflow remains unaltered. Those two fundamental reasons are the reasons this acquisition is ...
(Date:2/28/2017)... ... 2017 , ... The role of females in the military, ... civilian life. Body image dissatisfaction is largely unexamined among female veterans, a rapidly ... of chronic mental health conditions than female civilians. Female veterans also are more ...
(Date:2/27/2017)... ... 27, 2017 , ... Bo Chen, PhD is the recipient of the 2017 ... during the Plenary Session at ASLMS 2017, the Annual Conference of the American Society ... April 5-9, 2017. , During the Plenary Session on April 7, Dr. Chen ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... the alternative health care industry, announces Chris Brandl as its New Guest Director. ... vision and purpose to corporations throughout his career. He began his professional career ...
Breaking Medicine News(10 mins):